Login to Your Account

$350M in Pre-Market Milestones, Too

Ambit's Gambit Attracts Astellas; $40M Pays Perfect 'Flit' in AML?

By Randy Osborne

Monday, December 21, 2009
Ambit Biosciences Corp.'s potential $390 million deal with Astellas Pharma Inc. for FLT3 kinase inhibitors adds power to the push with oral small-molecule AC220, which just entered Phase II trials of the compound against acute myeloid leukemia in a patient subset that comprises about one-third of the newly diagnosed. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription